Literature DB >> 21737487

microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.

Francesca M Buffa1, Carme Camps, Laura Winchester, Cameron E Snell, Harriet E Gee, Helen Sheldon, Marian Taylor, Adrian L Harris, Jiannis Ragoussis.   

Abstract

microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated the benefits of a joint microRNA-mRNA analysis in breast cancer. Matched mRNA and microRNA global expression profiling was conducted in a well-annotated cohort of 207 cases with complete 10-year follow-up. Penalized Cox regression including microRNA expression, mRNA expression, and clinical covariates was used to identify microRNAs associated with distant relapse-free survival (DRFS) that provide independent prognostic information, and are not simply surrogates of previously identified prognostic covariates. Penalized regression was chosen to prevent overfitting. Furthermore, microRNA-mRNA relationships were explored by global expression analysis, and exploited to validate results in several published cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival). Four microRNAs were independently associated with DRFS in estrogen receptor (ER)-positive (3 novel and 1 known; miR-128a) and 6 in ER-negative (5 novel and 1 known; miR-210) cases. Of the latter, miR-342, -27b, and -150 were prognostic also in triple receptor-negative tumors. Coordinated expression of predicted target genes and prognostic microRNAs strengthened these results, most significantly for miR-210, -128a, and -27b, whose targets were prognostic in meta-analysis of several cohorts. In addition, miR-210 and -128a showed coordinated expression with their cognate pri-microRNAs, which were themselves prognostic in independent cohorts. Our integrated microRNA-mRNA global profiling approach has identified microRNAs independently associated with prognosis in breast cancer. Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737487     DOI: 10.1158/0008-5472.CAN-11-0489

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  164 in total

1.  Effects of oestrogen on microRNA expression in hormone-responsive breast cancer cells.

Authors:  Lorenzo Ferraro; Maria Ravo; Giovanni Nassa; Roberta Tarallo; Maria Rosaria De Filippo; Giorgio Giurato; Francesca Cirillo; Claudia Stellato; Silvana Silvestro; Concita Cantarella; Francesca Rizzo; Daniela Cimino; Olivier Friard; Nicoletta Biglia; Michele De Bortoli; Luigi Cicatiello; Ernesto Nola; Alessandro Weisz
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

2.  MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling.

Authors:  Laura Poliseno; Min Sup Song; Su Jung Song; Ugo Ala; Kaitlyn Webster; Christopher Ng; Gary Beringer; Nicolai J Brikbak; Xin Yuan; Lewis C Cantley; Andrea L Richardson; Pier Paolo Pandolfi
Journal:  Cell       Date:  2013-07-03       Impact factor: 41.582

3.  MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer.

Authors:  Adam R Wolfe; Arvind Bambhroliya; Jay P Reddy; Bisrat G Debeb; Lei Huo; Richard Larson; Li Li; Naoto T Ueno; Wendy A Woodward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-01-22       Impact factor: 7.038

Review 4.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

5.  Analysis of microRNA Regulation in Single Cells.

Authors:  Wendao Liu; Noam Shomron
Journal:  Methods Mol Biol       Date:  2021

6.  Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations.

Authors:  Ching-Hsuan Chen; Yen-Shen Lu; Ann-Lii Cheng; Chiun-Sheng Huang; Wen-Hung Kuo; Ming-Yang Wang; Ming Chao; I-Chun Chen; Chun-Wei Kuo; Tzu-Pin Lu; Ching-Hung Lin
Journal:  Oncologist       Date:  2019-08-01

7.  MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.

Authors:  Jessica Bockhorn; Kathy Yee; Ya-Fang Chang; Aleix Prat; Dezheng Huo; Chika Nwachukwu; Rachel Dalton; Simo Huang; Kaitlin E Swanson; Charles M Perou; Olufunmilayo I Olopade; Michael F Clarke; Geoffrey L Greene; Huiping Liu
Journal:  Breast Cancer Res Treat       Date:  2012-12-07       Impact factor: 4.872

8.  Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer.

Authors:  Stefano Volinia; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

9.  Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study.

Authors:  Jeannette T Bensen; Chiu Kit Tse; Sarah J Nyante; Jill S Barnholtz-Sloan; Stephen R Cole; Robert C Millikan
Journal:  Cancer Causes Control       Date:  2013-03-23       Impact factor: 2.506

10.  MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.

Authors:  Mithu Raychaudhuri; Holger Bronger; Theresa Buchner; Marion Kiechle; Wilko Weichert; Stefanie Avril
Journal:  Breast Cancer Res Treat       Date:  2017-02-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.